Dr. Michael Reihart, with Penn State Health, also explained who's most at risk for severe illness and how effective this year's vaccine is.

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...

Netflix's new limited series retells the story of a wellness influencer who rejected traditional cancer treatments in favor ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

In the ongoing battle against triple negative breast cancer, Vanderbilt researchers have uncovered a promising non-invasive ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...

The Elekta Unity MR-LINAC system combines MRI imaging with radiation therapy to target cancerous cells with pinpoint ...